C5AR1 Antibodies

C5a anaphylatoxin chemotactic receptor 1 (C5AR1)

Receptor for the chemotactic and inflammatory peptide anaphylatoxin C5a (PubMed:1847994, PubMed:8182049, PubMed:7622471, PubMed:9553099, PubMed:10636859, PubMed:15153520, PubMed:29300009).

The ligand interacts with at least two sites on the receptor: a high-affinity site on the extracellular N- terminus, and another site in the transmembrane region which activates downstream signaling events (PubMed:8182049, PubMed:7622471, PubMed:9553099).

Receptor activation stimulates chemotaxis, granule enzyme release, intracellular calcium release and superoxide anion generation (PubMed:10636859, PubMed:15153520). .

Gene Information

Human
Gene Name:	C5AR1
Uniprot:	P21730
Entrez:	728

Family

Belongs to:
G-protein coupled receptor 1 family

Alternative Names

C5a anaphylatoxin chemotactic receptor; C5A; C5aR; C5a-R; C5AR1; C5ARC5a anaphylatoxin receptor; C5R1C5a ligand; CD88 antigen; CD88; complement component 5 receptor 1 (C5a ligand); complement component 5 receptor 1; complement component 5a receptor 1; Complement Component C5a R1; Complement Component C5aR1

Molecular Weight

Mass (kDA):
39.336 kDA

Genomic Context

Human
Location:	19q13.32
Sequence:	19; NC_000019.10 (47309861..47322066)

Subcellular Localizations

Cell membrane; Multi-pass membrane protein. Cytoplasmic vesicle. Phosphorylated C5aR colocalizes with ARRB1 and ARRB2 in cytoplasmic vesicles.

Diseases

• Inflammation
• Arthritis
• Rheumatoid Arthritis
• Systemic Infection
• Inflammatory Response
• Malignant Neoplasms
• Autoimmune Diseases
• Asthma
• Allergy
• Infective Disorder
• Pertussis
• Familial Mediterranean Fever

• Reperfusion Injury
• Tissue Adhesions
• Inflammatory Disorder
• Tissue Damage
• Immune Complex Diseases
• Brucellosis
• Multiple Organ Failure

Pathways

• Complement Activation
• Chemotaxis
• Inflammatory Response
• Pathogenesis
• Phagocytosis
• Cell Migration
• Secretion
• Hypersensitivity
• Neutrophil Chemotaxis
• Localization
• Coagulation
• Transport
• Programmed Cell Death

• Protein Targeting
• Immune Response
• Proteolysis
• Virulence
• Leukocyte Migration
• Dendritic Cell Migration
• Monocyte Activation

PTMs

• Phosphorylation
• Formylation

• Cleavage
• Carboxylation

• Biotinylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/C5AR1

Boster Bio - Best Uses Of The C5AR1 Marker

If you have recently purchased a monoclonal antibody called Boster Bio's Anti-Hu CD88 Purified C5AR1 Marker, you may be wondering how to use it effectively. Fortunately, this article will provide you with an overview of the antibody's features and best uses in immunohistochemistry and clinical applications. This information is relevant to scientists worldwide, and will be useful in your decision-making process.

Boster Bio Anti-Hu CD88 Purified C5AR1 Monoclonal Antibody

If you're searching for an anti-Hu CD88 antibody, you've come to the right place. Boster Bio offers a broad range of primary antibodies that react with human, mouse, and rat proteins. These antibodies have been validated in Western Blotting, ELISA, and Flow Cytometry, making them highly useful for a variety of applications.

This monoclonal antibody targets the p62 protein in human cells. Various human tumors express this protein. This antibody is an excellent choice for tumor immunotherapy. It has been shown to effectively combat human breast cancer. In addition, it binds to other anti-Hu proteins such as BRCA1, HTATIP, and PARP10.

This monoclonal antibody was developed by recombinant technology, which has several advantages over traditional antibodies. First, it causes less harm to animals than traditional antibodies, and it's more reproducible and useful for a range of applications. Secondly, recombinant antibodies are suitable for multiple species and sequences, so they're useful in many applications.

Aldevron is a leading gene-centric life sciences company that provides research tools for the biomedical industry. With headquarters in the United Kingdom, the company employs over 280 people worldwide, and its subsidiaries span all of Central Europe. Its activities include research, development, and distribution of advanced medical devices, as well as laboratory diagnostics for human applications.

The company produces both polyclonal antibodies and recombinant antibodies. It uses a patented algorithm to design peptide antigens. They then validate the antigen identity using siRNA knockdown. DB Biotech produces high-quality rabbit clonal monospecific antibodies. You can also buy reagent kits, sandwich ELISA kits, and custom-made polyclonal antibodies through the company.

Human anaphylatoxin C5aR1 is an 74 residue glycopeptide produced by cleavage of the complement factor C5. It is an important mediator of inflammation and activates eosinophil and neutrophil chemotaxis. Human C5aR1 has 66% amino acid identity with mouse and rat C5aR1.

To test the anti-Hu CD88 Purified C5AR1, Boster Bio made a diluted version of this antibody. After treatment with the anti-Hu CD88 purified C5AR1 monoclonal antibody, the samples were plated in 96-well plates. Incubation was conducted at 37deg. Then, a log-phase Pseudomonas aeruginosa reporter strain was added. After 15 min of incubation, the cells were diluted to a final OD650 of 0.006. The bacteria were then quantified by measuring their luminescence output.

Boster Bio Anti-Hu CD88 Purized C5AR1 Monoclonal Ab has been extensively tested for its ability to block human immune responses. In addition to blocking C5a, it also inhibits the binding of the C5a receptor on myeloid cells. The results of these studies were published in a journal, Nature Communications. The authors thank the people who helped them make this publication.

Immunohistochemistry

This boster bio anti-Hu CD88 Purified C5AR1 Monoclonal Antibody reacted with Human, Mouse, and Rat cells. It was subsequently used to test for the presence of C5AR1 protein in human spleen cells. Moreover, the Boster bio anti-Hu CD88 C5AR1 antibody can also be used to study human spleen cell membranes.

The lack of C5aR1 prevented the development of behavioral deficits in mice aged 10 months. Furthermore, the brain's amyloid plaque load was not changed in these mice. Furthermore, immunohistochemical analysis demonstrated that IBA1-positive cells were not near the plaques. Furthermore, CD45-positive microglia were purified from infiltrating monocytes and their expression was analyzed by RNA-seq. The expression of phagosomal-lysosomal gene (PLG) was increased in Arctic/C5aR1 mice.

Clinical applications

The C5AR1 gene has been associated with a number of neurodegenerative disorders. When activated, C5aR1 retains its polarized localization in neural progenitor cells. As neural progenitor cells differentiate, their expression decreases. This cellular function makes C5aR1 a potential target for direct therapeutics. Here we review clinical applications of the C5AR1 gene marker.

This study examined the effects of the C5AR1 gene on mouse survival and outcomes in both high and low-pathogen-load settings. Mice infected with high and low-pathogen-load conditions developed severe sepsis. When mice in the two groups were compared using a log-rank test, the C5aR knockout mice exhibited a reduced mortality rate and improved overall clinical health.

In addition, these studies highlight the importance of the C5a gene for sepsis. The C5a gene is an important mediator of inflammation, and has been implicated in both pro and anti-inflammatory signaling. In a recent study, C5ar1-deficient mice had improved pathogen clearance, preserved liver function, and showed reduced levels of the anti-inflammatory cytokin interleukin-10.

This study also examined the correlation between the C5aR1 gene and the severity of COVID-19. The C5aR1 receptor is highly expressed in blood and pulmonary myeloid cells. Furthermore, anti-C5aR1 therapeutic monoclonal antibodies prevented C5a-mediated recruitment of myeloid cells, and inhibited acute lung injury in human C5aR1 knockout mice. These results suggest that the blocking of the C5aR1 axis may help prevent endothelialitis and excessive lung inflammation.

The effects of the C5aR1 gene on inflammatory outcomes in patients with autoimmune disease have been documented. It is known that autoimmune diseases such as atherosclerosis are accompanied by an adaptive immune response. This adaptive immune response results in an increased IFNg/IL-10 ratio and reduces the protective effects of C5aR-/ cells. Additionally, it causes a reduction in excretory liver function.

The apical membrane is the primary site of C5aR1 expression. C5aR1 colocalizes with atypical PKCz and Arl13b. Its expression is highest during the rosette stage and is confined to the apical plasma membrane. In addition, C5a is involved in maintaining cell polarity. The gene is regulated by endogenous C5a and exogenous C5a.